Andembry, Beyonttra, Rytelo Among 17 New Products To Receive EMA Backing

 
• By Eliza Slawther

The European Medicines Agency has recommended several new products for pan-EU approval, including CSL Behring’s drug for hereditary angioedema and BridgeBio’s treatment for transthyretin amyloidosis in cardiomyopathy patients.

More from EU CHMP

More from Agency Leadership